New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC) Grant

New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC) Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: US $75,000 - US $250,000
Last Updated: September 08, 2025

Summary

The grant titled 'New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)' by Pfizer aims to support independent medical education focused on innovative therapies such as EZH2 inhibition. It targets increasing awareness among healthcare professionals regarding the mechanisms of action of emerging therapies, the role of novel mechanisms in disease progression, and the need for novel therapies in mCRPC. This initiative underscores Pfizer's commitment to improving patient outcomes in oncology.

Overview

Pfizer Inc. Pfizer's purpose is breakthroughs that change patients’ lives. We pursue that goal relentlessly and innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today. Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies. New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC) Overview This competitive grant program seeks to support independent medical education addressing the new mechanisms in mCRPC including EZH2 inhibition and its possible role in prostate cancer and the continued unmet need for novel therapies in mCRPC. Project Types and Area of Interest Projects that will be considered for Pfizer support will focus on increasing healthcare professional awareness and understanding in the following areas: differentiated mechanism of action (MOA) of emerging therapies including EZH2 inhibition and its possible role in prostate cancerEZH2 and other novel mechanisms of disease (MOD) and their role in prostate cancer progressionthe investigational thesis of how concomitant EZH2 and AR inhibition may suppress prostate cancer while delaying or overcoming ARPi resistancethe continued unmet need for novel therapies in mCRPC mCRPC therapies beyond chemotherapy ongoing clinical trials that may be an option for patients today

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.